(Q58614520)
Statements
A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors (English)
Viktor Grünwald
Harald Singer
Ramon Salazar
Jose Luis Iglesias
Esther Casado
Martin Cullell-Young
Patrick Schöffski
7 September 2010
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference